Xilio Therapeutics, Inc. (XLO)
- Previous Close
1.1500 - Open
1.0000 - Bid 0.7632 x 200
- Ask 0.9525 x 100
- Day's Range
0.8354 - 1.0699 - 52 Week Range
0.6200 - 1.7000 - Volume
3,505,562 - Avg. Volume
1,378,011 - Market Cap (intraday)
47.323M - Beta (5Y Monthly) -0.23
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0900 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
xiliotx.comRecent News: XLO
View More
Performance Overview: XLO
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XLO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XLO
View MoreValuation Measures
Market Cap
59.54M
Enterprise Value
12.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.70
Price/Book (mrq)
3.38
Enterprise Value/Revenue
1.95
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.21%
Return on Equity (ttm)
-297.84%
Revenue (ttm)
9.27M
Net Income Avi to Common (ttm)
-54.3M
Diluted EPS (ttm)
-1.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
89.07M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--